Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease; A three-center study

A. Jubran, N. Gross, J. Ramsdell, R. Simonian, K. Schuttenhelm, M. Sax, D. J. Kaniecki, R. J.G. Arnold, F. A. Sonnenberg

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

The charts of 311 patients receiving theophylline (T) and 289 patients receiving ipratropium bromide (IB) for COPD were reviewed to determine the total costs and cost-effectiveness of these 2 agents in 3 different health- care settings. A direct cost-accounting method assessed cost, and a Markov decision-analysis model calculated cost-effectiveness. Costs to treat toxic effects were greater for T versus IB. The types and incidences of toxic effects, by drug, were similar among the three centers. Overall costs for T were $121.40 per patient per therapy-month versus $84.56 per patient per therapy-month for IB, as determined by the cost-accounting method. The marginal cost was $366 for T over IB when extrapolated over 1 year using the Markov model. The Markov model also predicted that patients receiving IB had a greater number of complication-free therapy-months (measurement of effectiveness) than patients receiving T. We conclude that treatment with IB was less costly and more cost-effective than T.

Original languageEnglish (US)
Pages (from-to)678-684
Number of pages7
JournalCHEST
Volume103
Issue number3
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease; A three-center study'. Together they form a unique fingerprint.

Cite this